Polyneuropathies in patients with diabetes mellitus

Authors: Peter Matejička;  Michal Minár
Authors‘ workplace: II. neurologická klinika LF UK a UNB, Nemocnica akad. L. Dérera, Bratislava
Published in: Forum Diab 2018; 7(3): 140-146
Category: Review Article


With an increasing prevalence of diabetes mellitus in the population predominantly of the world’s developed countries, the prevalence of complications of the primary disease linearly rises as well. One of them is diabetic neuropathy which to a large degree contributes to morbidity and indirectly also mortality related to diabetes. The term diabetic neuropathy is understood as peripheral neuropathy, caused by a direct effect of hyperglycemia engaged in a cascade of complex processes which damage the nervous fibres. The process results in the characteristic clinical picture reflecting the damage to the sensory, motor as well as autonomic peripheral nerves. The aim of this paper is not to produce a detailed analysis of the diagnosis of diabetic neuropathy, it aims to draw attention to the incidence of “non-diabetic” neuropathies in patients with diabetes mellitus. It is apparent that patients with diabetes and peripheral neuropathy are often incorrectly recorded with diabetic neuropathy, although their disorder may be autoimmunely conditioned, treatment-induced or toxic neuropathy. That is why we decided to also focus in this paper, apart from diabetic neuropathy, on the most frequently occurring peripheral neuropathies that could clinically mimic diabetic neuro­pathy, may be associated with it, or they occur along with it. These involve chronic demyelin­ation inflammatory polyneuropathy, metformin-induced neuropathy, “insulin neuritis” and alcohol neuropathy. With regard to the relatively high prevalence of the aforementioned neuropathies it is always necessary to consider their incidence also in patients with diabetes mellitus.

Key words:

antidiabetic drugs, axonal – demyelination changes, diabetes mellitus, electromyography, hyperglycemia, nervous fibres, neuropathy


1.    Edwards JL, Vincent AM, Cheng HT, Feld- man EL: Diabetic neuropathy: mechanisms to management. Pharmacol Ther 2008; 120(1): 1–34. Dostupné z DOI: <http://dx.doi.org/10.1016/j.pharmthera.2008.05.005>.
2.    Wild S, Roglic G, Green A et al. Global prevalence of diabetes: esti- mates for the year 2000 and projections for 2030. Diabetes Care 2004; 27(5): 1047–1053.
3.    Zimmet P, Alberti KG, Shaw J. Global and so- cietal implications of the diabetes epidemic. Nature 2001 ;414(6865): 782–787. Dostupné z DOI: <http://dx.doi.org/10.1038/414782a>.
4.    Dyck PJ, Thomas PK. Peripheral neuropathy. 4rd ed. Elsevier Saunders: 2005. ISBN 978–0721694917.
5.    Shaw J, Zimmet PZ. The epidemiology of diabetic neuropathy. Diabetes Rev 1999; 7(4): 245–252.
6.    Mazanec R, Bojar M, Nedělka T. Diabetická neuropatie z pohledu neurologa. Neurol Praxi 2009; 10(6): 378–383. 
7.    Tešić D, Cvijanović M, Pantelinac P. Akutna bolna neuro-patija. Med Pregl 1995;48(11–12):425–8.
8.    Cvijanović M, Ilin M, Slankamenac P et al. The sensitivity of electromyonurography in the diagnosis od Diabetic polyneuropathy. Med Pregl 2011; 64(1–2): 11–14.
9.    Thomas PK. Classification, differential diagnosis and staging of diabetic peripheral neuropathy. Diabetes 1997; 46(Suppl 2): S54–S57.
10.    Boulton AJ, Vinik AI, Arezzo JC et al. American Diabetes Association Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005 ;28(4): 956–962.
11.    Vinik A, Mehrabyan A, Colen L et al. Focal entrapment neuropathies in diabetes (Review). Diabetes Care 27(7): 1783–1788, 2004 
12.    Dimitropoulos G, Tahrani AA, Stevens MJ. Cardiac autonomic neuropathy in patients with diabetes mellitus. World J Diabetes 2014;5(1):17–39. Dostupné z DOI: <http://dx.doi.org/10.4239/wjd.v5.i1.17>.
13.    Pop-Busui R, Evans GW, Gerstein HC et al. [Action to Control CardiovascularRisk in Diabetes Study Group]. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care 2010; 33(7): 1578- 1584. Dostupné z DOI: <http://dx.doi.org/10.2337/dc10–0125>.
14.    Duby JJ, Campbell RK, Setter SM et al. Diabetic neuropathy: An intensive review. Am J Health-Syst Pharm 2004; 61(2): 160–173; quiz 175–6.
15.    Dyck PJ, Davies JL, Wilson DM et al. Risk Factors for Severity of Diabetic Polyneuropathy: intensive longitudinal assessment of the Rochester Diabetic Neuropathy Study cohort. Diabetes Care 1999; 22(9): 1479–1486.
16.    Meijer JW, Smit AJ, Lefrandt JD et al. Back to Basics in Diagnosing Diabetic Polyneuropathy With the Tuning Fork! Diabetes Care 2005; 28(9): 2201–2205. 
17.    Vinik AI, Pittenger GL, Barlow P et al. Diabetic Neuropathies. In: LeRoith D, Taylor SI, Olefsky JM. Diabetes mellitus A fundamental and clinical text. Lippincot Williams and Williams: Philadeplhia 2003: 1331–1363. ISBN 978–0781740975.
18.    Vondrová H. Diagnostika a diferenciální diagnostika diabetické polyneuropatie. Neurol Praxi 2010; 11(1): 41–44.
19.    Wilbourn AJ. The diabetic neuropathies. In: Brown WF, Bolton CF. Clinical electromyography. 2nd ed. Butterworths: Boston 1987; 329–364. ISBN 978–0409951639
20.    Vlcková-Moravcova E, Bednarik J, Belobradkova J et al. Small fibre involvement in diabetic patients with neuropathic foot pain. Diabet Med 2008; 25(6): 692–699. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1464–5491.2008.02446.x>.
21.    Gorson KC, Ropper AH. Additional causes for distal sensory polyneuropathy in diabetic patients. J Neurol Neurosurg Psychiatry 2006; 77(3): 354–358. Dostupné z DOI: <http://dx.doi.org/10.1136/jnnp.2005.075119>.
22.    Lozeron P, Nahum L, Lacroix C et al. Symptomatic diabetic and non-diabetic neuropathies in a series of 100 diabetic patients. J Neurol 2002, 249(5): 569–575. Dostupné z DOI: <http://dx.doi.org/10.1007/s004150200066>.
23.    Ziegler D. Painful diabetic neuropathy: advantage of novel drugs over old drugs? Diabetes Care 2009; 32(Suppl 2: S414–S419. Dostupné z DOI: <http://dx.doi.org/10.2337/dc09-S350>.
24.    Laughlin RS, Dyck PJ, Melton LJ et al. Incidence and prevalence of CIDP and the association of diabetes mellitus. Neurology 2009, 73(1): 39–45. Dostupné z DOI: <http://dx.doi.org/10.1212/WNL.0b013e3181aaea47>.
25.    Koller H, Kieseier BC, Jander S et al. Chronic inflammatory demyelinating polyneuropathy. N Engl J Med 2005; 352(13): 1343–1356. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMra041347>.
26.    Koski CL, Baumgarten M, Magder LS et al. Derivation and validation of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2009, 277(1–2): 1–8. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jns.2008.11.015>.
27.    Bednařík J. Chronická zánětlivá demyelinizační neuropatie. Neurológia Praxi 2016; 17(1): 16–21.
28.    Haq RU, Pendlebury WW, Fries TJ et al. Chronic inflammatory demyelinating polyradiculoneuropathy in diabetic patients. Muscle Nerve 2003, 27(4):465–470. Dostupné z DOI: <http://dx.doi.org/10.1002/mus.1250>.
29.    Bril V, Blanchetteb CM, Nooneb KM et al. The dilemma of diabetes in chronic inflammatory demyelinating polyneuropathy, J Diabetes Complications 2016; 30(7): 1401–1407. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jdiacomp.2016.05.007>.
30.    Viollet B, Guigas B, Sanz Garcia N et al Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) 2012;122(6):253–270. Dostupné z DOI: <http://dx.doi.org/10.1042/CS20110386>.
31.    Reinstatler L, Williamson RS, Garn JV et al. Association of biochemical B₁₂ deficiency with metformin therapy and vitamin B₁₂ supplements: the National Health and Nutrition Examination Survey, 1999–2006. Diabetes Care 2012; 35(2):327–333. Dostupné z DOI: <http://dx.doi.org/10.2337/dc11–1582>.
32.    Briani C, Dalla Torre C, Citton V et al. Cobalamin deficiency: clinical picture and radiological findings. Nutrients 2013; 5(11): 4521–4539. Dostupné z DOI: <http://dx.doi.org/10.3390/nu5114521>.
33.    Olt S, Oznas O. Investigation of the vitamin B12 deficiency with peripheral neuropathy in patients with type 2 diabetes mellitus treated using metformin. North Clin Istanb 2017; 4(3): 233–236. Dostupné z DOI: <http://dx.doi.org/10.14744/nci.2017.98705>.
34.    Ahmed MA, Muntingh G, Rheeder P. Vitamin B12 deficiency in metformin-treated type-2 diabetes patients, prevalence and associationwith peripheral neuropathy. BMC Pharmacol Toxicol 2016; 17(1): 44. Dostupné z DOI: <http://dx.doi.org/10.1186/s40360–016–0088–3>.
35.    Dabby R, Sadeh M, Lampl Y et al. Acute painful neuropathy induced by rapid correction of serum glucose levels in diabetic patients. Biomed Pharmacother 2009; 63(10): 707–709. Dostupné z DOI: <http://dx.doi.org/10.1016/j.biopha.2008.08.011>.
36.    Gibbons CH, Freeman R. Treatment-induced diabetic neuropathy: a reversible painful autonomic neuropathy. Ann Neurol 2010; 67(4): 534–41. Dostupné z DOI: <http://dx.doi.org/10.1002/ana.21952>.
37.    Tesfaye S, Vileikyte L, Rayman G et al. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev 2011; 27(7): 629–638. Dostupné z DOI: <http://dx.doi.org/10.1002/dmrr.1225.>.
38.    Elgendy R, Deschênes SS, Burns RJ et al. Alcohol consumption, depressive symptoms, and the incidence of diabetes-related complications. J Diabetes 2018. Dostupné z DOI: <http://dx.doi.org/10.1111/1753–0407.12822>. 
39.    Ambler Z. Poruchy periferních nervů. Triton: Praha 2013. ISBN 9788073877057.
40.    Mazanec, R, Baumgartner D, Potočková V. Toxická neuropatie. Neurol Praxi 2017; 18(1): 20–24.

Diabetology Endocrinology Internal medicine
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account